Home > Drugs A-Z > Meclizine Hydrochloride

Meclizine Hydrochloride (Rebel Distributors Corp.)

Available Formats

Dosage Form Package Information Links
TABLET 15 TABLET in 1 BOTTLE (21695-237-15) Label Information
TABLET 90 TABLET in 1 BOTTLE (21695-237-90) Label Information
TABLET 30 TABLET in 1 BOTTLE (21695-237-30) Label Information
TABLET 40 TABLET in 1 BOTTLE (21695-237-40) Label Information
TABLET 10 TABLET in 1 BOTTLE (21695-237-10) Label Information

Complete Meclizine Hydrochloride Information

  • DESCRIPTION

    Meclizine hydrochloride, an oral antiemetic, is a white, slightly yellowish, crystalline powder which has a slight odor and is tasteless. It has the following structural formula:

    Chemical Structure
    C25H27CIN22HCIH2O M.W. 481.89

    The chemical name is 1-(p-chloro-alpha-phenylbenzyl)-4-(m-methyl-benzyl) - piperazine dihydrochloride monohydrate.

    Meclizine Hydrochloride Tablets are available in 12.5 mg, and *25 mg strengths for oral administration.

    *Contains FD&C Yellow #5 (see PRECAUTIONS).

    Each tablet contains the following inactive ingredients: colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, starch, stearic acid and other ingredients. In addition, the 12.5 mg tablet contains FD&C Blue #1; and the 25 mg tablet contains D&C Yellow #10 and FD&C Yellow #5.


  • CLINICAL PHARMACOLOGY

    Meclizine hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.


  • INDICATIONS AND USAGE

    For the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.


  • CONTRAINDICATIONS

    Meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.


  • WARNINGS

    Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

    Patients should avoid alcoholic beverages while taking the drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland. Do not give to children under 12 years of age unless directed by a doctor.


  • PRECAUTIONS

    The Meclizine Hydrochloride Tablets, 25 mg contain FD&C Yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow #5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

    Usage in Children: Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended under 12 years of age.

    Usage in Pregnancy:Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine hydrochloride increases the risk of abnormalities when administered during pregnancy.

    Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine hydrochloride, or any other medication should be used during pregnancy only if clearly necessary.


  • ADVERSE REACTIONS

    Drowsiness, dry mouth, and on rare occasions, blurred vision have been reported.


  • DOSAGE AND ADMINISTRATION

    Motion Sickness: The initial dose of 25 to 50 mg meclizine hydrochloride, should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.


  • HOW SUPPLIED

    Meclizine Hydrochloride Tablets, USP 12.5 mg - blue, oval tablets debossed with “034” on one side and “par” on the other side. Tablets may contain characteristic dye spots. They are supplied in bottles of 30 (NDC 21695-383-30).

    Meclizine Hydrochloride Tablets, USP 25 mg - yellow, oval tablets debossed with “035” on one side and “par” on the other side. They are supplied in bottles of 10 (NDC 21695-237-10), 15 (NDC 21695-237-15), 30 (NDC 21695-237-30), 40 (NDC 21695-237-40) and 90 (NDC 21695-237-90).

    Dispense in tight, light-resistant containers as defined in the USP.

    Store at controlled room temperature 15°-30°C (59°-86°F).

    Manufactured by:

    PAR PHARMACEUTICAL COMPANIES, INC.

    Spring Valley, NY 10977

    Repackaged by:

    REBEL DISTRIBUTORS CORP

    Thousand Oaks, CA 91320

     


  • Principal Display Panel

    Meclizine 12.5mg


  • INGREDIENTS AND APPEARANCE
    MECLIZINE HYDROCHLORIDE 
    meclizine hydrochloride tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:21695-383(NDC:49884-034)
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Meclizine Hydrochloride (UNII: HDP7W44CIO) (Meclizine - UNII:3L5TQ84570) Meclizine Hydrochloride 12.5 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    LACTOSE (UNII: J2B2A4N98G)  
    Magnesium stearate (UNII: 70097M6I30)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    Stearic Acid (UNII: 4ELV7Z65AP)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    Product Characteristics
    Color BLUE Score no score
    Shape OVAL Size 5mm
    Flavor Imprint Code Par;034
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:21695-383-30 30 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA087127 06/03/1981
    MECLIZINE HYDROCHLORIDE 
    meclizine hydrochloride tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:21695-237(NDC:49884-035)
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Meclizine Hydrochloride (UNII: HDP7W44CIO) (Meclizine - UNII:3L5TQ84570) Meclizine Hydrochloride 25 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    LACTOSE (UNII: J2B2A4N98G)  
    Magnesium stearate (UNII: 70097M6I30)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    Stearic Acid (UNII: 4ELV7Z65AP)  
    FD&C YELLOW NO. 5 (UNII: I753WB2F1M)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    Product Characteristics
    Color YELLOW Score no score
    Shape OVAL Size 6mm
    Flavor Imprint Code Par;035
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:21695-237-10 10 in 1 BOTTLE
    2 NDC:21695-237-15 15 in 1 BOTTLE
    3 NDC:21695-237-30 30 in 1 BOTTLE
    4 NDC:21695-237-40 40 in 1 BOTTLE
    5 NDC:21695-237-90 90 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA087128 06/03/1981
    Labeler - Rebel Distributors Corp. (118802834)
    Establishment
    Name Address ID/FEI Business Operations
    Rebel Distributors Corp. 118802834 RELABEL, REPACK